
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
A new study has identified retinal imaging as a tool that can distinguish cases of abusive brain trauma with 93% accuracy.






